Align Technology Responds to EU Investigation
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 50 minutes ago
0mins
Source: Newsfilter
- Investigation Response: Align Technology has responded to the European Commission's June 30 announcement regarding an investigation, asserting its commitment to global competition laws and the belief that fair competition fosters innovation and improves outcomes for doctors and patients.
- iTero Platform Strength: The iTero intraoral scanning platform performs millions of scans annually, supporting diverse clinical workflows while ensuring clinical quality and patient safety, showcasing its competitive edge in the digital dentistry market.
- Market Impact: Since 2018, the iTero scanner has facilitated over 24 million scans by healthcare professionals, highlighting its extensive application and influence in the teeth-straightening market, driving diversification in digital dentistry solutions.
- Commitment to Cooperation: Align Technology expresses its intention to fully cooperate with the European Commission's investigation, anticipating that the review will reflect the vibrancy and compliance of the teeth-straightening market, further solidifying its market position.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ALGN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ALGN
Wall Street analysts forecast ALGN stock price to rise
13 Analyst Rating
8 Buy
4 Hold
1 Sell
Moderate Buy
Current: 173.430
Low
169.00
Averages
198.70
High
220.00
Current: 173.430
Low
169.00
Averages
198.70
High
220.00
About ALGN
Align Technology, Inc. is a global medical device company that designs, manufactures, and sells the Invisalign system of clear aligners, iTero intraoral scanners, and exocad computer-aided design and computer-aided manufacturing (CAD/CAM) software for digital orthodontics and restorative dentistry. The Company provides Align Digital Platform. Its segments include Clear Aligner, and Imaging Systems and CAD/CAM Services (Systems and Services). The Clear Aligner segment consists of comprehensive products, non-comprehensive products and non-case products. Its comprehensive products include Invisalign Comprehensive and Invisalign First. The Company's non-case products include retention products, Invisalign training and adjusting tools. It offers up to four sets of custom clear aligners called Vivera retainers. The Systems and Services segment consists of its iTero intraoral scanning systems. Its services include subscription software, disposables, rentals, leases and pay per scan services.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Align Technology Responds to EU Investigation
- Investigation Response: Align Technology has responded to the European Commission's June 30 announcement regarding an investigation, asserting its commitment to global competition laws and the belief that fair competition fosters innovation and improves outcomes for doctors and patients.
- iTero Platform Strength: The iTero intraoral scanning platform performs millions of scans annually, supporting diverse clinical workflows while ensuring clinical quality and patient safety, showcasing its competitive edge in the digital dentistry market.
- Market Impact: Since 2018, the iTero scanner has facilitated over 24 million scans by healthcare professionals, highlighting its extensive application and influence in the teeth-straightening market, driving diversification in digital dentistry solutions.
- Commitment to Cooperation: Align Technology expresses its intention to fully cooperate with the European Commission's investigation, anticipating that the review will reflect the vibrancy and compliance of the teeth-straightening market, further solidifying its market position.
See More
European Commission Launches Antitrust Investigation into Align Technology
- Antitrust Investigation Launched: The European Commission has initiated an antitrust investigation into Align Technology, alleging that the company tied its Invisalign products to its iTero intra-oral scanners, potentially stifling competition and harming its reputation.
- Concerns Over Market Dominance: The Commission is worried that Align Technology may have unfairly leveraged its market-leading Invisalign clear aligners by effectively forcing dental professionals to purchase the iTero scanner to order Invisalign for their patients, which could lead to market inequities.
- Restrictive Interoperability Strategy: The investigation focuses on Align's so-called 'restrictive interoperability strategy,' which includes refusal to approve competing state-of-the-art scanners and refusal to accept dental professionals' submissions of scans, potentially hindering industry innovation.
- Uncertain Financial Outlook: Although Align Technology forecasts Q2 revenue between $1.04 billion and $1.06 billion and reaffirms a 3%-4% revenue growth for 2026, the antitrust investigation may negatively impact its future performance.
See More
Align Technology Announces Board Leadership Transition
- Board Leadership Change: Align Technology has announced a formal transition of its board leadership effective July 1, 2026, with longtime Chairman C. Raymond Larkin, Jr. retiring after over 20 years of service, succeeded by independent director Kevin Conroy, ensuring a seamless leadership handover.
- Continued Involvement: Although Larkin will retire, he will remain on the board and serve on the Nominating and Governance Committee until December 31, 2026, highlighting the company's commitment to stable governance during the transition.
- New Chairman's Background: Incoming Chairman Kevin Conroy has served as an independent director since December 2023 and has chaired the board's Compensation and Human Capital Committee since January 2026, indicating his extensive experience in corporate governance.
- Financial Performance: Align Technology forecasts Q2 revenue between $1.04 billion and $1.06 billion while reaffirming a revenue growth target of 3%-4% for 2026, with a non-GAAP EPS of $2.58, exceeding expectations by $0.29, reflecting the company's robust financial performance.
See More
Align Technology Announces Chairman Retirement and Successor
- Chairman Retirement: Align Technology announced that C. Raymond Larkin, Jr. will retire on July 1, 2026, after over 20 years of service on the Board, during which he provided strategic guidance that ensured Align's leadership in digital dentistry through various growth phases.
- New Chairman Appointment: Kevin Conroy will succeed Larkin as Chairman, having served as an independent director since December 2023 and Chair of the Compensation and Human Capital Committee since January 2026, expected to leverage his extensive experience in healthcare and technology to drive Align's innovation and growth.
- Leadership Transition Impact: Under Larkin's leadership, Align treated approximately 22.8 million patients, and Conroy's succession is seen as pivotal for Align to continue expanding its digital orthodontics market and enhancing shareholder value, especially amid increasing competition in the medical device sector.
- Future Development Outlook: Conroy expressed his commitment to closely collaborate with the management team to promote innovation and broaden access to digital orthodontics, which is anticipated to create long-term value for shareholders and further solidify Align's position in the global market.
See More
Market Capitalization Comparison: Align Technology vs. UDR
- Market Cap Comparison: Align Technology's market capitalization stands at $12.43 billion, compared to UDR's $12.23 billion, indicating Align's relative strength in the market, which may attract more interest from large funds.
- Investor Misconceptions: Many novice investors often compare stocks solely based on share price, overlooking the significance of market capitalization, which can lead to misguided investment decisions, highlighting the need for investor education.
- Market Positioning Impact: The market cap difference between Align and UDR results in distinct positioning within investment portfolios, with Align likely favored by large-cap funds while UDR may attract mid-cap fund attention, affecting liquidity and market performance.
- Stock Performance: At Thursday's close, Align's stock rose approximately 4.9%, while UDR dipped 0.1%, reflecting positive market sentiment towards Align, which could further drive its market cap growth.
See More
Resmed's Acquisition Fuels Growth in Residential Care Software Segment
- Acquisition-Driven Growth: Resmed's strategic acquisitions, including MEDIFOX DAN, have successfully expanded its Residential Care Software segment, which is expected to continue supporting growth in the coming quarters and enhance synergies within its Sleep and Breathing Health franchise.
- Mask Innovation and Resupply: In Q3 of fiscal 2026, Resmed's mask and other sales increased by 14%, driven by new product designs and resupply strategies, which not only improved patient comfort but also supported customer retention in long-term therapy.
- Enhanced Financial Flexibility: As of Q3 fiscal 2026, Resmed reported $1.66 billion in cash, with short-term debt at $260 million and long-term debt at $404 million, resulting in a debt-to-capital ratio improvement to 5.9%, indicating relatively low financial risk.
- Macroeconomic Challenges: Despite Resmed's solid financial performance, it faces challenges from macroeconomic pressures and intense competition, which could impact demand and operating costs, potentially leading to negative effects on the company's overall performance.
See More
Align Technology Responds to EU Investigation
- Investigation Response: Align Technology has responded to the European Commission's June 30 announcement regarding an investigation, asserting its commitment to global competition laws and the belief that fair competition fosters innovation and improves outcomes for doctors and patients.
- iTero Platform Strength: The iTero intraoral scanning platform performs millions of scans annually, supporting diverse clinical workflows while ensuring clinical quality and patient safety, showcasing its competitive edge in the digital dentistry market.
- Market Impact: Since 2018, the iTero scanner has facilitated over 24 million scans by healthcare professionals, highlighting its extensive application and influence in the teeth-straightening market, driving diversification in digital dentistry solutions.
- Commitment to Cooperation: Align Technology expresses its intention to fully cooperate with the European Commission's investigation, anticipating that the review will reflect the vibrancy and compliance of the teeth-straightening market, further solidifying its market position.
See More
European Commission Launches Antitrust Investigation into Align Technology
- Antitrust Investigation Launched: The European Commission has initiated an antitrust investigation into Align Technology, alleging that the company tied its Invisalign products to its iTero intra-oral scanners, potentially stifling competition and harming its reputation.
- Concerns Over Market Dominance: The Commission is worried that Align Technology may have unfairly leveraged its market-leading Invisalign clear aligners by effectively forcing dental professionals to purchase the iTero scanner to order Invisalign for their patients, which could lead to market inequities.
- Restrictive Interoperability Strategy: The investigation focuses on Align's so-called 'restrictive interoperability strategy,' which includes refusal to approve competing state-of-the-art scanners and refusal to accept dental professionals' submissions of scans, potentially hindering industry innovation.
- Uncertain Financial Outlook: Although Align Technology forecasts Q2 revenue between $1.04 billion and $1.06 billion and reaffirms a 3%-4% revenue growth for 2026, the antitrust investigation may negatively impact its future performance.
See More
Align Technology Announces Board Leadership Transition
- Board Leadership Change: Align Technology has announced a formal transition of its board leadership effective July 1, 2026, with longtime Chairman C. Raymond Larkin, Jr. retiring after over 20 years of service, succeeded by independent director Kevin Conroy, ensuring a seamless leadership handover.
- Continued Involvement: Although Larkin will retire, he will remain on the board and serve on the Nominating and Governance Committee until December 31, 2026, highlighting the company's commitment to stable governance during the transition.
- New Chairman's Background: Incoming Chairman Kevin Conroy has served as an independent director since December 2023 and has chaired the board's Compensation and Human Capital Committee since January 2026, indicating his extensive experience in corporate governance.
- Financial Performance: Align Technology forecasts Q2 revenue between $1.04 billion and $1.06 billion while reaffirming a revenue growth target of 3%-4% for 2026, with a non-GAAP EPS of $2.58, exceeding expectations by $0.29, reflecting the company's robust financial performance.
See More
Align Technology Announces Chairman Retirement and Successor
- Chairman Retirement: Align Technology announced that C. Raymond Larkin, Jr. will retire on July 1, 2026, after over 20 years of service on the Board, during which he provided strategic guidance that ensured Align's leadership in digital dentistry through various growth phases.
- New Chairman Appointment: Kevin Conroy will succeed Larkin as Chairman, having served as an independent director since December 2023 and Chair of the Compensation and Human Capital Committee since January 2026, expected to leverage his extensive experience in healthcare and technology to drive Align's innovation and growth.
- Leadership Transition Impact: Under Larkin's leadership, Align treated approximately 22.8 million patients, and Conroy's succession is seen as pivotal for Align to continue expanding its digital orthodontics market and enhancing shareholder value, especially amid increasing competition in the medical device sector.
- Future Development Outlook: Conroy expressed his commitment to closely collaborate with the management team to promote innovation and broaden access to digital orthodontics, which is anticipated to create long-term value for shareholders and further solidify Align's position in the global market.
See More
Market Capitalization Comparison: Align Technology vs. UDR
- Market Cap Comparison: Align Technology's market capitalization stands at $12.43 billion, compared to UDR's $12.23 billion, indicating Align's relative strength in the market, which may attract more interest from large funds.
- Investor Misconceptions: Many novice investors often compare stocks solely based on share price, overlooking the significance of market capitalization, which can lead to misguided investment decisions, highlighting the need for investor education.
- Market Positioning Impact: The market cap difference between Align and UDR results in distinct positioning within investment portfolios, with Align likely favored by large-cap funds while UDR may attract mid-cap fund attention, affecting liquidity and market performance.
- Stock Performance: At Thursday's close, Align's stock rose approximately 4.9%, while UDR dipped 0.1%, reflecting positive market sentiment towards Align, which could further drive its market cap growth.
See More
Resmed's Acquisition Fuels Growth in Residential Care Software Segment
- Acquisition-Driven Growth: Resmed's strategic acquisitions, including MEDIFOX DAN, have successfully expanded its Residential Care Software segment, which is expected to continue supporting growth in the coming quarters and enhance synergies within its Sleep and Breathing Health franchise.
- Mask Innovation and Resupply: In Q3 of fiscal 2026, Resmed's mask and other sales increased by 14%, driven by new product designs and resupply strategies, which not only improved patient comfort but also supported customer retention in long-term therapy.
- Enhanced Financial Flexibility: As of Q3 fiscal 2026, Resmed reported $1.66 billion in cash, with short-term debt at $260 million and long-term debt at $404 million, resulting in a debt-to-capital ratio improvement to 5.9%, indicating relatively low financial risk.
- Macroeconomic Challenges: Despite Resmed's solid financial performance, it faces challenges from macroeconomic pressures and intense competition, which could impact demand and operating costs, potentially leading to negative effects on the company's overall performance.
See More
